Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a biotechnology company based in Frederick, Maryland, that focuses on innovative cell therapy for autoimmune diseases, announced on October 30, 2025, the granting of employment inducement awards to two recent hires.
On October 27, 2025, one employee received an option to acquire 50,000 shares of the company”s common stock. The exercise price for this option is set at $8.85, which corresponds to the closing price of the stock on the Nasdaq Global Market on the grant date. Subsequently, on October 29, 2025, another employee was granted an option to purchase 2,650 shares at an exercise price of $8.20, also based on the closing trading price from that day.
These options were issued in accordance with the Amended and Restated 2018 Employment Inducement Incentive Award Plan, having received approval from the company”s board of directors. The stock options for the first employee will vest at a rate of 25% on October 27, 2026, followed by three equal annual installments, resulting in full vesting by October 27, 2029. The second employee”s options will follow a similar vesting schedule, with 25% vesting on October 29, 2026, and the remainder vesting in equal installments over the next three years, culminating in full vesting by October 29, 2029.
Each option is valid for a term of ten years and was granted under Rule 5635(c)(4) of the Nasdaq Listing Rules, serving as a significant incentive for the new employees joining the company.
About Cartesian Therapeutics
Cartesian Therapeutics is at the forefront of developing cell therapies aimed at treating autoimmune disorders. The company is advancing its lead product, Descartes-08, a CAR-T therapy currently in Phase 3 clinical trials targeting generalized myasthenia gravis, along with Phase 2 trials for systemic lupus erythematosus. Moreover, a Phase 2 basket trial is planned to explore additional autoimmune indications.
The pipeline also features Descartes-15, a next-generation autologous anti-BCMA CAR-T therapy, which is being assessed in a Phase 1 trial for patients with multiple myeloma. To learn more about Cartesian Therapeutics, visit www.cartesiantherapeutics.com or follow the company on LinkedIn or X, previously known as Twitter.
Contact Information:
Investor Contact:
Megan LeDuc
Associate Director, Investor Relations
[email protected]
Media Contact:
David Rosen
Argot Partners
[email protected]
